A patient with rapidly-evolving severe MS is having doubts about the decision to be treated with cladribine. Should she abort the cladribine and have AHSCT?
I just found out the Mexican HSCT centres have changed their protocols and are now using a standard dose of cyclophosphamide. So the reference above to HSCT-light probably does not apply to their treatment protocol anymore.
I hope you don,t mind my message I wasn't sure how to contact you. I was diagnosed in 2008my consultant advised me that has I had no obvious symptoms no treatment was required ( he informed me of the difficulty in getting treatment unless you were showing symptoms)In 2014 I was informed by my Nurse over the telephone I had progressed to SPMS I was put on Ocrevus in 2018 my mobility is the biggest problem I cannot walk unaided and as I am aware Ocrevus does not cure just slows things down. I however am progressing. I have now been told I can transfer to Ofemtumumab if I would like been reading up on this has a very similar write up to Ocrevus the only benefit would be the injection would be administered at home which would be easier as I have a 43 year old disabled daughter (I am 62) my MRI is stable but I have had no obvious side effects from Ocrevus and no obvious benefits I am finding it extremely difficult to decide do you know anything about Ofemtumumab
Dear sir, I'm wondering why you suggest Alemtuzumab over HSCT in her case. As I understand, alemtuzumab is more selective and less cytotoxic for the brain (please correct me if I'm wrong), but carries its own risks like chances of developing secondary autoimmunity. Also, wouldn't HSCT be better if she were to plan getting COVID vaccine as her immune system would recover sooner due to stem cell administration and with Alemtuzumab, or even cladribine, she would have to wait till her immune cells repopulate naturally?
An interesting read, though i feel for the patient who's situation is not dissimilar to my own. A question on the HSCT-light description. HSCT forums claim that the dose of cyclophosphamide is the same in Russia and Mexico as it is in the UK and it is the ATG / Rituxumab protocol which separates the approaches. Is this incorrect?
I just found out the Mexican HSCT centres have changed their protocols and are now using a standard dose of cyclophosphamide. So the reference above to HSCT-light probably does not apply to their treatment protocol anymore.
I hope you don,t mind my message I wasn't sure how to contact you. I was diagnosed in 2008my consultant advised me that has I had no obvious symptoms no treatment was required ( he informed me of the difficulty in getting treatment unless you were showing symptoms)In 2014 I was informed by my Nurse over the telephone I had progressed to SPMS I was put on Ocrevus in 2018 my mobility is the biggest problem I cannot walk unaided and as I am aware Ocrevus does not cure just slows things down. I however am progressing. I have now been told I can transfer to Ofemtumumab if I would like been reading up on this has a very similar write up to Ocrevus the only benefit would be the injection would be administered at home which would be easier as I have a 43 year old disabled daughter (I am 62) my MRI is stable but I have had no obvious side effects from Ocrevus and no obvious benefits I am finding it extremely difficult to decide do you know anything about Ofemtumumab
Dear sir, I'm wondering why you suggest Alemtuzumab over HSCT in her case. As I understand, alemtuzumab is more selective and less cytotoxic for the brain (please correct me if I'm wrong), but carries its own risks like chances of developing secondary autoimmunity. Also, wouldn't HSCT be better if she were to plan getting COVID vaccine as her immune system would recover sooner due to stem cell administration and with Alemtuzumab, or even cladribine, she would have to wait till her immune cells repopulate naturally?
An interesting read, though i feel for the patient who's situation is not dissimilar to my own. A question on the HSCT-light description. HSCT forums claim that the dose of cyclophosphamide is the same in Russia and Mexico as it is in the UK and it is the ATG / Rituxumab protocol which separates the approaches. Is this incorrect?